Introduction
============

Nanotechnology has been labeled the new technology of the 21st century. With the rapid development of nanotechnology, potential applications of nanomaterials in medicine have been researched widely in recent years.[@b1-ijn-13-6987] Nanomaterials have developed rapidly, and traditional nanomaterials are now unable to meet the needs of some special industries or high technology. Multifunctional Janus nanoparticles (NPs) have become a hot spot in the research field of nanomaterials in recent years.[@b2-ijn-13-6987],[@b3-ijn-13-6987] Due to their fascinating hierarchical superstructures, Janus particles are promising candidates for a variety of high-quality applications, such as catalysis, textiles, sensors, therapeutic treatments, and imaging diagnosis.[@b4-ijn-13-6987],[@b5-ijn-13-6987] Recently, Janus NPs have gained extensive attention in the field of chemistry and biology, resulting from combined chemical, magnetic, optical, and electronic interactions at the solid-state heterojunction of the particles.[@b6-ijn-13-6987] In this system, two or more nanocomponents with different properties are linked together, which allows the simultaneous realization of multiple functions. In particular, Janus nanostructures may introduce dual- or multimodal responses to enable diagnostics and therapeutics to be performed simultaneously for biomedical applications.[@b7-ijn-13-6987]

Because of their excellent optical performance and electrical properties, TiO~2~ NPs have a wide range of applications. Nanosized particles have been used for the photodynamic and sonodynamic treatment of preclinical cancer.[@b8-ijn-13-6987],[@b9-ijn-13-6987] Photodynamic therapy (PDT) is a method of joint use of light and special drugs (photosensitizers) for the treatment of diseased cells and tissue therapy.[@b10-ijn-13-6987] The application of TiO~2~ NPs in the field of antitumor therapy has aroused widespread concern. The field of molecular imaging has been gaining interest in the research world. Magnetic resonance imaging (MRI)-contrast agents can increase diagnostic accuracy and imaging sensitivity for detecting pathological changes and also provide previously undetectable physiological information.[@b11-ijn-13-6987] Super-paramagnetic iron oxide has been classified as biocompatible, because it is processed by cells as part of physiological iron metabolism, has good chemical stability and better magnetic responsiveness, and requires only nanomolar concentrations to produce good images.[@b12-ijn-13-6987],[@b13-ijn-13-6987]

In our previous work, multifunctional Fe~3~O~4~-TiO~2~ NPs with Janus structure for MRI and potential PDT were synthesized, using Fe~3~O~4~ as the MRI-contrast agent and TiO~2~ as an inorganic photosensitizer for PDT.[@b14-ijn-13-6987] The results showed that Fe~3~O~4~-TiO~2~ NPs had good *T*~2~-weighted MRI performance and MCF7 cells incubated with Fe~3~O~4~-TiO~2~ NPs were killed under ultraviolet-light irradiation. Compared with traditional organic photosensitizers, inorganic TiO~2~ photosensitizers have more stable PDT performance due to their nanosize and antiphotodegradable stability.[@b15-ijn-13-6987] However, in vivo biomedical applications using TiO~2~ NPs have been limited because of shallow penetration and ultraviolet light being a well-known mutagen.

Due to the promising multifunctional properties of Janus Fe~3~O~4~-TiO~2~ NPs in cancer diagnosis and treatment, in vitro and in vivo toxicity and biodistribution of this material should be thoroughly evaluated before providing basic information for its bioapplication in the future. As we know, few NPs should be applied biologically in humans due to their widely known toxicity. Interestingly, while the toxicity of single TiO~2~ NPs or Fe~3~O~4~ NPs has been widely studied, toxicity evaluation on Janus Fe~3~O~4~-TiO~2~ NPs is still lacking.[@b16-ijn-13-6987]--[@b19-ijn-13-6987] Janus Fe~3~O~4~-TiO~2~ NPs will be used mainly through intravenous injection for diagnosis and treatment in medicine. Intravenous injection of nanomaterials directly into the blood without passing through the normal absorption process has raised public concerns regarding the toxicity to humans in nanomedicine.[@b20-ijn-13-6987] In this study, rats were treated with intravenous tail injections with a single dose of Janus Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs in saline. Thirty days after treatment, rats were killed, then hematological, biochemical, element-content, histopathological, and molecular protein expression were analyzed.

Methods
=======

Materials
---------

Biochemical and hematological analyses were performed with a 7600-110 autoanalyzer (Hitachi Ltd., Tokyo, Japan) and blood analyzer (XT-1800i; Sysmex Corporation, Kobe, Japan), respectively. Metal content (Ti and Fe) was detected by inductively coupled plasma (ICP) mass spectrometry (MS; Nexion 300D; PerkinElmer Inc., Waltham, MA, USA) and ICP optical emission spectroscopy (Optima 2100DV; PerkinElmer Inc.). The monoclonal antibodies p38, phosphorylated p38 (p-p38), JNK, phosphorylated JNK (p-JNK), ERK, HO1, c-Jun, cleaved caspase 3, Bcl2, Bax, p50, p53, Nrf2, Akt, and GAPDH were obtained from Cell Signaling Technology (Danvers, MA, USA). Sprague Dawley rats were obtained from Zhejiang Provincial Laboratory Animal Science Center (Hangzhou, China). Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs were obtained from our cooperation team at the Chinese Academy of Materials (Ningbo, China).

Fe~3~O~4~-TiO~2~ NP and TiO~2~ NP preparation
---------------------------------------------

Fe~3~O~4~-TiO~2~ composite NPs were synthesized by the solvent-thermal method as stated in our previous work.[@b14-ijn-13-6987] First, TiO~2~ NPs (about 7--10 nm) were synthesized based on a previously reported method.[@b21-ijn-13-6987] Then, prepared TiO~2~ NPs were centrifuged and washed with ethanol and redispersed in 10 mL *n*-hexane. Next, ferric acetylacetonate (17 mg) was dissolved in oleic acid (4 mL) and *n*-octyl alcohol (12 mL), then added to a Teflon tube that had been autoclaved for 3 hours at 240°C. Then, the mixture was washed with ethanol and dispersed into a nonpolar solvent. TiO~2~ NPs (1 mL dispersed in *n*-hexane) were dropped into the ferric acetylacetonate solution. The mixture was stirred for 4 hours before increasing the temperature to 70°C, in order to evaporate the *n*-hexane. Finally, the mixture was cooled to room temperature and transferred into a reaction kettle. The reaction temperature was kept at 240°C for 3 hours. Finally, the prepared Fe~3~O~4~-TiO~2~ NPs were centrifuged, washed with ethanol three times, and dispersed into 10 mL cyclohexane. Later, F127 triblock polymer was used to transfer the phase from organic to aqueous. Fe~3~O~4~-TiO~2~ NPs (1 mL) were added dropwise to F127 (700 mg) and dispersed in CHCl~3~ (70 mL). After the solution had been stirred for 4 hours, water (10 mL) was added and CHCl~3~ evaporated using a rotatory evaporator. Finally, the aqueous dispersed NPs were washed with ethanol and redispersed in water.

Detection of size distribution
------------------------------

High-resolution transmission electron microscopy (HRTEM) of NPs was obtained with a 2100 microscope (JEOL, Tokyo, Japan) at 200 kV. X-ray diffraction patterns were collected on a D8 Advance (Bruker, Billerica, MA, USA) powder diffractometer using CuKα radiation (40 kV, 40 mA) with a step size of 0.02° in 2θ and 3 seconds/step. Loaded Fe and Ti content in Fe~3~O~4~-TiO~2~ NPs was measured by ICP optical emission spectroscopy.

Experimental design and preparation
-----------------------------------

All animals were kept in stress-free, hygienic, and animal-friendly conditions (relative humidity 60%±10%, room temperature 20°C±2°C, and 12-hour light/dark cycle). Food and water were available ad libitum. All animal-study protocols were approved by the Ningbo University Institutional Animal Care and Use Committee (AEWC-2016--151), and experiments followed the Chinese "Regulation on the management of laboratory animals", adopted in 1988. Healthy male rats (12 weeks old) were selected and randomly divided into one control group and six experimental groups (5, 15, and 30 mg/kg Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs, respectively) with six rats in each group. The observation period was 30 days. A staged approach to dosing method was used for selection of the dose ranges. When determining chemical dosage, care was taken to prevent any severe toxicity in the animal that could affect absorption, metabolism, distribution, or excretion.[@b22-ijn-13-6987] Following this principle, the highest treatment dose for both NP types was set at 30 mg/kg for this study. Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs were suspended in normal saline and vortexed. Nanomaterials were administered intravenously into the tail vein. The control group received the same amount of saline (2 mL/rat) as treated groups.

Organ weight:body weight coefficients and hematological, biochemical, and electrolyte analysis
----------------------------------------------------------------------------------------------

At the end of the experiment, the body weights of all rats were recorded before the rats were killed. The average weight of rats from the control group was 417.16±11.53 g, and the average weights of the three TiO~2~ NP groups and three Fe~3~O~4-~TiO~2~ NP groups were 399.16±13.56 g, 401.50±16.48 g, 409.80±26.60 g, 427.83±23.16 g, 396.71±27.86 g, and 413.80±25.74 g, respectively. No significant difference in body weight was found among the seven animal groups. Rats were anesthetized with chloral hydrate by intraperitoneal injection. Blood was collected for hematological, biochemical, and electrolyte analysis in anticoagulant or coagulation-promoting test tubes. Blood was analyzed for hematological parameters using the Sysmex XT-1800i. Enzymatic parameters related to liver, kidney, and cardiac function were detected using the Hitachi 7600-110, and lipid- and serum-electrolyte analysis was also included. Then, rats were killed, and brains, hearts, livers, spleens, lungs, kidneys, and testes taken out and weighed immediately. Organ weight:body weight coefficients were calculated as the ratio of wet-tissue weight (g) to body weight (100 g).

ICP-MS
------

Tissue samples (0.5 g) of brain, heart, liver, spleen, lungs, kidneys, and testes were weighed and digested with 5 mL HNO~3~ in a test tube overnight. The mixture was stirred and heated at reflux at 170°C for 1 hour and then diluted to 50 mL with deionized water. Tissue-sample tubes were washed three times in deionized water.

Histopathological examination
-----------------------------

After weighing, organs were fixed immediately in 10% formalin for histopathological examination. Tissue samples were examined to check pathological effects caused by different treatments. Formalin-fixed tissue was stored at 4°C until examination. Tissue samples were processed using standard histological laboratory techniques. Using a microtome, tissue sections were cut to approximately 3--4 µm thickness, then stained with H&E using a standard protocol.

Western blot analysis
---------------------

Liver-tissue samples were frozen in liquid nitrogen and stored at −80°C until use. Tissue samples (20--30 mg) were ground with a mortar and pestle in liquid nitrogen. Lysis buffer (100 µL) containing phenylmethylsulfonyl fluoride (10 mmol/L) and EDTA (1 mM) was then added to the tissue residue for 4 hours. Then, the lysate was centrifuged at 12,000 rpm for 15 minutes at 4°C to obtain the supernatant. Protein concentrations of the supernatant were determined by the bicinchoninic acid method. The supernatant was mixed with 5× loading buffer (4:1 in volume) and boiled for 5 minutes for Western blot. Polyacrylamide-stacking (6%) gels and resolving (10%) gels were used to separate the proteins of different molecular weights. Immunoblots for expression of p38, p-p38, JNK, p-JNK, HO-1, ERK, c-Jun, cleaved caspase 3, Bcl2, Bax, P50, p53, Nrf2, Akt, and GAPDH were detected. All antibodies for Western blot in this study were purchased from Cell Signaling Technology. Tris-buffered saline Tween 20 with 5% skim milk was used to block the membranes for 3.5 hours before incubation overnight with primary antibodies (1:1,000 dilution). After three washes with Tris-buffered saline Tween 20, membranes were incubated with the corresponding secondary antibodies (1:4,000 dilution) for 1.5 hours. A 4200SF imaging processing system (Tanon, Shanghai, China) was used for Western blot analysis.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 16.0. One-way ANOVAs were used for organ-coefficient comparison and hematological, biochemical, electrolyte, and accumulation analysis. Student's *t*-test was used to compare differences between experimental groups and the control group. *P*\<0.05 was considered statistically significant. Results are presented as means ± SD.

Results
=======

Average size distribution of Fe~3~O~4~-TiO~2~ NPs
-------------------------------------------------

Images of Fe~3~O~4~-TiO~2~ NPs were captured by TEM and HRTEM ([Figure 1](#f1-ijn-13-6987){ref-type="fig"}). [Figure 1A](#f1-ijn-13-6987){ref-type="fig"} shows that most of the Fe~3~O~4~-TiO~2~ NPs had a Janus structure and Fe~3~O~4~ had cubic spherical particles and narrower particle-size distribution. The average size distribution of the Fe~3~O~4~-TiO~2~ NPs was about 20--25 nm, detected using a Tecnai F20 with energy-dispersive spectroscopy. As such, the experimental materials met the requirements to be classified as NPs. [Figure 1B](#f1-ijn-13-6987){ref-type="fig"} shows the HRTEM of Fe~3~O~4~-TiO~2~ NPs and shows that Fe~3~O~4~ was coupled with TiO~2~ NPs to form a Janus structure. [Figure 1C](#f1-ijn-13-6987){ref-type="fig"} shows that average TiO~2~ NP size distribution was about 7--10 nm, the particles well dispersed, and no reunion of TiO~2~ NPs was observed. [Figure 2](#f2-ijn-13-6987){ref-type="fig"} shows the X-ray diffraction spectra of Fe~3~O~4~-TiO~2~ NPs, Fe~3~O~4~ NPs, and TiO~2~ NPs. It can be observed that the peaks of Fe~3~O~4~-TiO~2~ NPs include TiO~2~ peaks with anatase structure and Fe~3~O~4~ peaks with cubic structure.

Organ weight:body weight coefficients
-------------------------------------

Organ weight:body weight coefficients of the rats are shown in [Table 1](#t1-ijn-13-6987){ref-type="table"}. No significant differences were found in organ coefficients of the heart, lungs, kidneys, brain, or testes in Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs compared to the control group. In 15 mg/kg Fe~3~O~4~-TiO~2~ NPs, liver and spleen coefficients were higher than the control group (*P*\<0.05).

Hematological analysis
----------------------

Hematological effects are shown in [Table 2](#t2-ijn-13-6987){ref-type="table"}. Only in 5 mg/kg TiO~2~ NPs was the white blood cell (WBC) count significantly less than that of the control group. There was no significant change in any other hematological parameter.

Biochemical analysis
--------------------

Biochemical parameters of liver, renal, lipid, cardiac, and electrolyte profiles are shown in [Table 3](#t3-ijn-13-6987){ref-type="table"}. Liver profiles showed that no significant difference in serum levels of total bilirubin, albumin, or total protein was observed in any of the treated animals. In the TiO~2~ NP-treated groups, Alanine aminotransferase (ALT) at 5 and 30 mg/kg and AST at 30 mg/kg were significantly elevated. In the Fe~3~O~4~-TiO~2~ NP-treated groups, aspartate transaminase (AST) at 5 and 30 mg/kg and ALT in all treated groups were significantly decreased. Alkaline phosphatase (ALP) showed no significant difference among any of the treatment groups. Renal profiles showed that uric acid (UrcA) in the Fe~3~O~4~-TiO~2~ NP-treated groups was significantly decreased. Serum low-density-lipoprotein cholesterol (LDL-C) levels in TiO~2~ NP-treated rats at 5 mg/kg and Fe~3~O~4~-TiO~2~ NPs at 30 mg/kg were significantly higher than the control group. No significant changes were observed for triglycerides or high-density-lipoprotein cholesterol levels in any of the animals treated.

All treated animals showed a slight decrease in serum creatine kinase (CK) levels, but only TiO~2~ NPs at 5 mg/kg showed a significant decrease when compared to control. Fe~3~O~4~-TiO~2~ NPs in all treatment groups significantly decreased serum CK-MB levels, while TiO~2~ NPs only at 30 mg/kg serum CK-MB levels decreased when compared with the control group. Serum-potassium levels in Fe~3~O~4~-TiO~2~ NPs at 15 mg/kg were significantly lower than in the control group. Serum-magnesium levels in all treated animals showed a decrease, but no statistical significance was found. Serum-phosphorus levels in Fe~3~O~4~-TiO~2~ NP-treated rats at 5 and 30 mg/kg were significantly decreased when compared to the control group.

Analysis of metal content in tissue
-----------------------------------

Total Ti levels in tissue were used for evaluating the presence or distribution of Ti composed in Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs in the body. Ti content in different tissue types is shown in [Figure 3](#f3-ijn-13-6987){ref-type="fig"}. After treatment with Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs, Ti levels in cardiac tissue showed a tendency to increase in all treated animals in a dose-related manner, although no statistical significance was found, which might have been due to individual differences. Ti content in the liver in TiO~2~ NP-treated animals at 15 and 30 mg/kg showed a significant elevation (*P*\<0.05). Although Ti content also showed a tendency to increase in the livers of Fe~3~O~4~-TiO~2~ NP-treated animals, no statistical significance was found. In spleens and lungs of the TiO~2~ NP-treated animals, Ti content was significantly increased at 15 and 30 mg/kg. No significant difference was found in Ti content in spleens and lungs in any Fe~3~O~4~-TiO~2~ NP-treated groups. Treatments of Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs resulted in only a slight change in Ti content in the brain and testes (*P*\>0.05).

In addition, [Figure 3](#f3-ijn-13-6987){ref-type="fig"} also indicates that at 30 days after treatment, TiO~2~ NPs had still not excreted entirely from the body. Accumulative ability of Ti in different organs ranked as liver \> spleen \> lungs \> heart \> kidneys \> brain \> testes. Fe content in rat tissue is shown in [Figure 4](#f4-ijn-13-6987){ref-type="fig"}. After treatment, no significant change in Fe content in the heart, liver, spleen, lungs, kidneys, brain, or testes was found in any of the TiO~2~ NP- or Fe~3~O~4~-TiO~2~ NP-treatment groups, except for TiO~2~ NP-treated rats at 30 mg/kg, which showed a significant decrease. Fe content in different organs ranked as spleen \> heart \> lungs \> kidneys \> brain \> testes \> liver.

Histopathological examination
-----------------------------

Liver histopathological images are shown in [Figure 5](#f5-ijn-13-6987){ref-type="fig"}. At 5 mg/kg, liver tissue in Fe~3~O~4~-TiO~2~ NP-treated rats had no obvious abnormal pathological changes compared with the control. However, at the high treatment dose (30 mg/kg), Fe~3~O~4~-TiO~2~ NPs induced certain lymphocytic infiltration at the periphery of the liver. Small focal-like inflammatory cell infiltration appeared around the portal area or hepatic vein in the 5 and 15 mg/kg TiO~2~ NP groups. Lymphocyte aggregation was observed in the 30 mg/kg TiO~2~ NP group. TiO~2~ NPs induced more severe adverse changes than Fe~3~O~4~-TiO~2~ NPs at the same treatment dose.

Lung histopathological images are illustrated in [Figure 6](#f6-ijn-13-6987){ref-type="fig"}. TiO~2~ NPs at 15 and 30 mg/kg induced inflammatory cell infiltration around blood vessels of lung tissue, cell-nodule formation, smaller alveoli, and thicker interstitium when compared with the control group. At 30 mg/kg, Fe~3~O~4~-TiO~2~ NPs showed similar effects of alveoli getting smaller and interstitium getting thicker.

Spleen histopathological images are shown in [Figure 7](#f7-ijn-13-6987){ref-type="fig"}. Increased red-pulp area and severe congestion were observed in both TiO~2~ NP- and Fe~3~O~4~-TiO~2~ NP-treated animals at 15 and 30 mg/kg. Comparatively, at the same treatment dose, TiO~2~ NPs induced more severe adverse changes than Fe~3~O~4-~TiO~2~ NPs.

Histopathological results for the kidneys are shown in [Figure 8](#f8-ijn-13-6987){ref-type="fig"}. As the dose of TiO~2~ NPs increased, the volume of glomerular and number of cells increased. At 30 mg/kg in both Fe~3~O~4~-TiO~2~ NP and TiO~2~ NP groups, renal tubular epithelial cells were cloudy and swollen. In TiO~2~ NP-treated animals, granule denaturation and membrane vacuolar degeneration were observed in the epithelial cells of the renal tubule.

Western blot analysis
---------------------

Western blot analysis on protein expression of p38, p-p38, JNK, p-JNK, HO-1, ERK, c-Jun, cleaved caspase 3, Bcl2, Bax, p50, p53, Nrf2, Akt, and GAPDH in liver tissue is shown in [Figure 9](#f9-ijn-13-6987){ref-type="fig"}. Significant increases in the expression of p-p38, JNK, p-JNK, HO1, c-Jun, cleaved caspase 3, Bax, p50, and p53 was observed in both Fe~3~O~4~-TiO~2~ NP- and TiO~2~ NP-treated groups with a dose relationship when compared to the control group. An increase in ERK expression was observed only in 5 mg/kg TiO~2~ NP- and 15 and 30 mg/kg Fe~3~O~4~-TiO~2~ NP-treated animals. Both Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs significantly decreased Bcl2 in a dose-related manner. No obvious effects of p38 or Nrf2 expression were observed in Fe~3~O~4~-TiO~2~ NP- or TiO~2~ NP-treated animals. Similarly to ERK expression, Akt expression was enhanced in 5 mg/kg TiO~2~ NP- and 15 and 30 mg/kg Fe~3~O~4~-TiO~2~ NP-treated animals.

Discussion
==========

In view of the potential applications of Janus Fe~3~O~4~-TiO~2~ NPs in the diagnosis and treatment of cancer, biosafety evaluation on these newly developed Janus NPs through intravenous injection in rats was conducted. Research has shown that intravenous injection of Fe~3~O~4~-TiO~2~ NPs is a practical method for radiotherapy.[@b23-ijn-13-6987] In order to compare maternal with synthesized material, TiO~2~ NPs used to synthesize Fe~3~O~4~-TiO~2~ NPs were also evaluated in this study.

Intravenous injection of Fe~3~O~4~-TiO~2~ NPs induced liver injury
------------------------------------------------------------------

At 30 days after treatment, all rats had survived. In the first 2 days after 30 mg/kg intravenous injection, toxic symptoms indicated by less physical activity and less intake of food and water were observed in some of the Fe~3~O~4~-TiO~2~ NP- and TiO~2~ NP-treated animals compared to the control group. In this study, we found that in the 15 mg/kg Fe~3~O~4~-TiO~2~ NP group, liver coefficients of rats were significantly higher than the control group. This was consistent with histopathological results of distortion of normal liver architecture due to congestion and a decrease in liver sinusoids compared to the controls. In hematological analysis, a significant decrease in WBCs and lymphocytes was found in the 5 mg/kg TiO~2~ NP-treatment group. Other TiO~2~ NP-treated animals also showed a slight decrease in these two parameters, but with no significant difference. Studies suggest that a low WBC count is usually the result of a medical condition that disrupts the function of the bone marrow or destroys WBCs. These conditions may include infections, congenital disorders, certain cancers, cancer therapies, and certain drug administration.[@b24-ijn-13-6987],[@b25-ijn-13-6987] A low lymphocyte or WBC count may increase the body's risk of infection. This result was in agreement with the lymphoid aggregates found in liver tissue at the 5 mg/kg TiO~2~ NPs dose.

In this study, no obvious pathological changes were observed in the histology of the heart in any treatment group. A significant decrease in CK levels was found only in 5 mg/kg TiO~2~ NP-treated animals. However, a significant decrease in CK-MB levels was found in all Fe~3~O~4~-TiO~2~ NP-treated animals and 30 mg/kg TiO~2~ NP-treated animals. Normally, CK-MB is produced mainly by the myocardium and liver. Muscles can also produce a small amount of CK-MB.[@b26-ijn-13-6987] The cause of the decrease in CK-MB levels is not clear, and more studies are necessary in order to clarify the exact mechanism of this phenomenon.

Previous research has shown that TiO~2~ NP treatment through oral administration can increase hepatocyte necrosis.[@b27-ijn-13-6987] Our study showed that TiO~2~ NPs accumulated in the liver, spleen, and lungs, which suggests that these organs might be the major places where TiO~2~ NPs were metabolized. Fabian et al investigated tissue distribution after intravenous administration of TiO~2~ NPs and found that the levels were highest in the liver, followed by the spleen and lungs.[@b28-ijn-13-6987] Mohamed and Hussien also confirmed that when TiO~2~ NPs enter the blood, it is very easy for the particles to reach and accumulate in the most critical organs of the body, such as the brain, spleen, liver, kidneys, and lungs, causing injury to these organs and tissue.[@b29-ijn-13-6987] Many studies have shown that accumulation of TiO~2~ NPs can be observed in the liver, lungs, kidneys, and spleen after intravenous, intraperitoneal, or dermal administration.[@b22-ijn-13-6987],[@b28-ijn-13-6987],[@b30-ijn-13-6987]

Interestingly, in this study, we found no significant increase in Ti content in the liver, spleen, or lungs in any of the Fe~3~O~4~-TiO~2~ NP-treatment groups when compared with controls. ICP-MS analysis showed a very small amount of Ti accumulation in the kidneys and spleen in Fe~3~O~4~-TiO~2~ NP-treatment groups, but there was no significant accumulation in brain tissue. The results may partly explain why Ti accumulation, histopathological changes, hepatocyte apoptosis of the liver, and a certain degree of alteration in liver function was more severe in the TiO~2~ NP-treatment groups than the Fe~3~O~4~-TiO~2~ NP groups. The reason for this phenomenon might be the interaction of Fe~3~O~4~ with TiO~2~ NPs. Fe~3~O~4~ seems to act as a beneficial factor in Janus Fe~3~O~4~-TiO~2~ NP-metabolism process in the body.

Although TiO~2~ has been classified by the International Agency for Research on Cancer as a group 2B carcinogen, human epidemiological studies on TiO~2~ have provided inadequate evidence of carcinogenicity. Research indicates that delayed hypersensitivity to Ti and its oxides may induce a health risk for individuals with higher susceptibility.[@b31-ijn-13-6987] Therefore, excessive Ti accumulation in the body over a long period has the potential to induce certain adverse effects in the body.

To check how the molecular mechanism of TiO~2~ NP and Fe~3~O~4~-TiO~2~ NP treatment affected the rat liver, the signaling cascade of stress-activated MAPK-pathway-related proteins were detected. Recent studies in vivo have shown that the MAPK cascade converging on JNK and p38 plays a central role.[@b32-ijn-13-6987] Among the three MAPKs, ERK is activated by various cytokines and growth factors and plays a central role in cell growth and differentiation.[@b33-ijn-13-6987] Research has shown that JNK can mediate both cell-survival and cell-death pathways, which are often determined by the duration of JNK activation. Sustained JNK is important in mediating apoptosis and necrosis.[@b34-ijn-13-6987],[@b35-ijn-13-6987] JNK signaling is associated with survival, cell death, differentiation, proliferation, and tumorigenesis in hepatocytes. In nonparenchymal liver cells, such as hepatic macrophages (Kupffer cells) and hepatic stellate cells, JNK is involved in inflammation and fibrosis.[@b36-ijn-13-6987] JNK and p38 MAPKs, also called stress-activated MAPKs, are preferentially activated by proinflammatory cytokines, such as TNFα, and environmental and genotoxic stresses. After activation, stress-activated MAPKs phosphorylate specific serine/threonine residues of target substrates and exert a variety of cellular functions, such as cell death, survival, proliferation, migration, and inflammation.

In this study, Western blot analysis revealed that ERK increased in the 30 mg/kg Fe~3~O~4~-TiO~2~ NP group. A significant increase in expression of JNK and p-JNK in liver tissue occurred in both Fe~3~O~4~-TiO~2~ NP- and TiO~2~ NP-treatment groups compared to controls. Expression of p-p38 was increased in the 5 mg/kg TiO~2~ NP group. These results suggest that both Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs have certain effects on MAPK-cascade proteins.

Signal pathways involved in apoptosis were also investigated in this study. We found that both Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs significantly increased expression of the proapoptotic proteins Bax and cleaved caspase 3, but decreased expression of the antiapoptotic protein Bcl2. Bcl2 inhibits apoptosis, while Bax promotes apoptosis, and the ratio of the Bcl2--Bax protein complex is directly related to the occurrence of apoptosis. Some researchers have even named the Bcl2:Bax ratio the "apoptosis switch". When the Bax protein is dominant, apoptosis occurs, whereas when the Bcl2 protein is dominant, the cell survives.[@b37-ijn-13-6987] The reason the intensity of Bcl2- and Bax-expression bands obtained in this study seems not to follow a correlated pattern might be the difference in incubation and development times of different membranes during our Western blot experiments. Cleaved caspase 3 expression means activation of cell-death protease. HO1 expression increased in all treatment groups, especially Fe~3~O~4~-TiO~2~ NP groups. Under normal physiological conditions, the expression and vitality of HO1 are low. As a stress-responsive protein, HO1 can be activated under different stress conditions and has a strong antioxidant effect.[@b38-ijn-13-6987] Nrf2 is a transcription factor and has been shown to play an essential role in the antioxidant response element-mediated expression of phase 2 detoxifying enzymes and stress-inducible genes.[@b39-ijn-13-6987] Nrf2-protein expression in liver tissue showed no significant change in any of the treated groups. Our results suggest that both Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs activated oxidative- and antioxidative-related signal proteins in rat liver cells, although certain differences may exist between the two materials.

Intravenous injection of Fe~3~O~4~-TiO~2~ NPs led to slight inflammation in lungs, kidneys, and spleen
------------------------------------------------------------------------------------------------------

Renal profiles showed that UrcA in all Fe~3~O~4~-TiO~2~ NP-treatment groups were significantly decreased in a dose-- response manner. Low UrcA may occur by numerous causes, such as low dietary zinc intake. Wang et al suggested that serum-UrcA levels lower than healthy controls could be used as a useful biomarker for multiple sclerosis diagnosis.[@b40-ijn-13-6987] Serum LDL-C levels with TiO~2~ NP treatment at 5 mg/kg and Fe~3~O~4~-TiO~2~ NP treatment at 30 mg/kg were significantly higher than controls. High LDL-C levels in the blood may deposit in the heart, brain, or other parts of the artery wall, and gradually form atherosclerotic plaques, blocking the corresponding blood vessels. An increase in serum LDL-C levels is often used to evaluate the risk of future heart disease.[@b41-ijn-13-6987]

In the spleen and lungs, Ti content increased significantly in the 15 and 30 mg/kg TiO~2~ NP-treatment groups compared to controls. However, no significant increases in Ti content in the spleen or lungs in any of the Fe~3~O~4~-TiO~2~ NP-treatment groups was observed. These results indicate that compared to Fe~3~O~4~-TiO~2~ NPs, TiO~2~ NPs seem to be accumulated more easily in the lung and spleen, which then brings harmful risks to the organs.

Lung histopathological examination showed that mild and focal inflammatory infiltrates in the pulmonary parenchyma in both Fe~3~O~4~-TiO~2~ NP- and TiO~2~ NP-treated rats, suggesting that slight inflammation occurred. An increase in red-pulp area can be caused by different pathological conditions, such as portal hypertension, cardiac failure, or extramedullary hematopoiesis. Spleen histopathological examination indicated that in the TiO~2~ NP-treatment group at 15 mg/kg, the red-pulp area in the spleen increased when compared with the same dose in the Fe~3~O~4~-TiO~2~ NP group.

The electrolyte profile showed a significant decrease in potassium in the 15 mg/kg Fe~3~O~4~-TiO~2~ NP group, while other groups also showed a decrease, but without any statistical difference. Martínez-Valles et al found that hypokalemia was associated with small-cell lung cancer.[@b42-ijn-13-6987] Serum phosphate was significantly decreased at 5 and 30 mg/kg in the Fe~3~O~4~-TiO~2~ NP groups, and TiO~2~ NPs at 15 mg/kg also showed a significant decrease. Organic phosphorus is essential for numerous normal physiological functions, including skeletal development, mineral metabolism, cell-membrane phospholipid content and function, energy transfer through mitochondrial metabolism, and cell signaling. Although serum phosphate reflects only a minor fraction of total body phosphorus, this decrease may cause a reduction in urinary phosphorus excretion, which may further lead to metabolic acidosis and a decrease in growth and thyroid hormones.[@b43-ijn-13-6987] Serum chlorine in the Fe~3~O~4~-TiO~2~ NP treatment at 30 mg/kg group showed a significant increase. An increase in serum-chlorine levels has been linked to renal disease, renal failure, and renal tubular acidosis.[@b44-ijn-13-6987] No obvious pathological changes were observed in the brain, heart, or testes in any of the treatment groups in this study. Due to the uncertainty in the extrapolation of toxicological data from experimental animals to humans, more studies will be needed before elaborating on detailed mechanisms of these findings and the biosafety of Fe~3~O~4~-TiO~2~ NPs for clinical use.[@b45-ijn-13-6987]

Conclusion
==========

In summary, the major findings of the present study include a certain degree of alteration in liver function and electrolyte and lipid parameters in both Fe~3~O~4~-TiO~2~ NP- and TiO~2~ NP-treated rats. Both materials induced a certain degree of damage in lungs, spleen, liver, and kidneys. To a certain degree, we conclude that Janus Fe~3~O~4~-TiO~2~ NPs are less toxic than TiO~2~ NPs in animal experiments. The data from this study provide pharmacokinetic and biokinetic information for Janus Fe~3~O~4~-TiO~2~ NPs. This will be very important in determining the biosafety of Fe~3~O~4~-TiO~2~ NP use in nanomedicine.
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![Images of Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs captured by TEM and HRTEM.\
**Notes:** (**A**) TEM of Fe~3~O~4~-TiO~2~ NPs; (**B**) HRTEM of Fe~3~O~4~-TiO~2~ NPs; (**C**) TEM of TiO~2~ NPs.\
**Abbreviations:** HRTEM, high-resolution TEM; NPs, nanoparticles; TEM, transmission electron microscopy.](ijn-13-6987Fig1){#f1-ijn-13-6987}

![Fe~3~O~4~-TiO~2~ NPs captured by X-ray diffraction.\
**Abbreviation:** NPs, nanoparticles.](ijn-13-6987Fig2){#f2-ijn-13-6987}

![Ti content in tissue of rats after treatment with Fe~3~O~4~-TiO~2~ NPs and TiO~2~ NPs.\
**Note:** ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001 compared with control.\
**Abbreviations:** NPs, nanoparticles; Con, control.](ijn-13-6987Fig3){#f3-ijn-13-6987}

![Fe content in tissue of rats after treatment with Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs.\
**Abbreviations:** NPs, nanoparticles; Con, control.](ijn-13-6987Fig4){#f4-ijn-13-6987}

![Photomicrography of liver histopathology.\
**Notes:** Images (magnification 10×) represent histopathological sections of the liver. Arrows represent small focal-like inflammatory cell infiltration around the hepatic portal (HP) area in the 5 mg/kg TiO~2~ NP group and around the hepatic vein (HV) in the 15 mg/kg TiO~2~ NP group, and lymphocyte aggregation in the 30 mg/kg TiO~2~ NP group. Dark arrows represent liver hepatocyte (H) granule degeneration and small stove liver-cell shrinkage in both Fe~3~O~4~-TiO~2~ NP and TiO~2~ NP groups at 30 mg/kg.\
**Abbreviations:** NPs, nanoparticles; Con, control; S, sinus; K, Kupffer cells.](ijn-13-6987Fig5){#f5-ijn-13-6987}

![Photomicrography of lung histopathology.\
**Notes:** Images (magnification 10×) represent histopathological sections of the lung. Dark arrow in the 15 mg/kg TiO~2~ NP group represents edema and exudation around bronchi and a large amount of inflammatory cell infiltration. Dark arrows in the 30 mg/kg TiO~2~ NP group represent a large number of inflammatory infiltration around bronchi.\
**Abbreviations:** NP, nanoparticle; Con, control; A, alveolar space; B, bronchioles; H, histiocytes; AS, alveolar septa; V, veins.](ijn-13-6987Fig6){#f6-ijn-13-6987}

![Photomicrography of spleen histopathology.\
**Note:** Images (magnification 10×) represent histopathological sections of the spleen.\
**Abbreviations:** NPs, nanoparticles; Con, control; RP, red pulp; WP, white pulp; T, trabeculae; CA, central artery; GC, germinal center.](ijn-13-6987Fig7){#f7-ijn-13-6987}

![Photomicrography of kidney histopathology.\
**Notes:** Images (magnification 40×) represent histopathological sections of kidneys. No significant pathological changes were observed in the hearts in either Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs treated animals (data not shown).\
**Abbreviations:** NPs, nanoparticles; Con, control; G, glomerular; T, tubular epithelial cells.](ijn-13-6987Fig8){#f8-ijn-13-6987}

![Signal protein expression in liver tissue.\
**Notes:** (**A**) Protein-expression levels of p38, p-p38, JNK, p-JNK, HO1, ERK, c-Jun, cleaved caspase 3, Bcl2, Bax, p50, p53, Nrf2, Akt, and GAPDH; (**B**) relative protein expression (normalized to GAPDH). ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001 compared with control.\
**Abbreviations:** NPs, nanoparticles; Con, control.](ijn-13-6987Fig9){#f9-ijn-13-6987}

###### 

Organ weight:body weight coefficients of rats after 30 days' exposure to Fe~3~O~4~-TiO~2~ NPs or TiO~2~ NPs through intravenous injection

  Parameters   Control (mg/kg)   TiO~2~ NPs (mg/kg)   Fe~3~O~4~-TiO~2~ NPs (mg/kg)                                              
  ------------ ----------------- -------------------- ------------------------------ ------------ ------------ ---------------- ------------
  Heart        3.28±0.35         3.29±0.21            3.37±0.33                      3.45±0.30    3.32±0.16    3.58±0.38        3.23±0.25
  Liver        31.80±1.45        33.30±1.48           32.10±2.98                     34.40±2.46   34.70±1.73   35.50±1.55^\*^   33.60±1.67
  Spleen       1.95±0.25         2.31±0.42            2.13±0.37                      2.17±0.11    2.20±0.57    2.79±0.88^\*^    2.12±0.16
  Lung         3.79±0.40         3.42±0.42            3.69±0.48                      3.37±0.16    3.35±0.47    3.80±0.62        3.20±0.28
  Kidney       6.45±0.28         6.81±0.67            6.86±0.74                      6.63±0.35    6.38±0.41    6.69±0.31        6.13±0.51
  Brain        4.23±0.61         4.23±0.66            4.60±0.80                      4.78±0.43    4.46±0.50    4.94±0.33        4.59±0.15
  Testis       6.13±1.02         7.12±0.48            6.85±0.58                      6.99±0.50    6.49±0.40    6.91±0.79        6.85±0.36

**Note:** Results given as means ± SD (^\*^*P*\<0.05 compared with control).

**Abbreviation:** NPs, nanoparticles.

###### 

Hematological analysis after different treatments

  Parameters                  Control         TiO~2~ NPs (mg/kg)   Fe~3~O~4~-TiO~2~ NPs (mg/kg)                                                 
  --------------------------- --------------- -------------------- ------------------------------ --------------- -------------- -------------- --------------
  WBCs (×10^9^/L)             10.72±2.56      7.38±1.35^a^         8.76±1.72                      8.24±1.76       8.78±1.29      8.79±2.21      11.66±2.28
  Neutrophils (%)             14.86±7.15      17.07±7.20           19.42±9.34                     20.10±7.47      23.23±4.82     16.96±5.83     22.36±6.58
  Lymphocytes (%)             83.56±2.83      79.53±8.50           84.40±3.78                     81.36±6.27      76.45±5.19     80.17±3.05     77.84±5.82
  Monocytes (%)               2.22±1.60       1.97±0.97            3.38±1.58                      2.88±0.64       1.68±2.20      3.31±1.73      2.90±2.68
  Eosinophils (%)             0.88±0.26       0.53±0.26            0.94±0.29                      2.25±3.87       0.87±0.51      0.79±0.32      0.92±0.37
  Basophils (%)               0.10±0.07       0.12±0.15            0.04±0.05                      0.08±0.04       0.05±0.05      0.09±0.04      0.06±0.05
  Neutrophils (%)             1.53±0.90       1.26±0.56            1.68±0.74                      1.59±0.47       2.08±0.61      1.43±0.46      2.66±1.01
  Lymphocytes (%)             8.36±0.79       5.79±1.42^a^         7.30±1.41                      6.61±1.51       6.49±0.74      7.02±1.94      8.84±1.52
  Monocytes (%)               0.22±0.16       0.16±0.11            0.29±0.13                      0.24±0.10       0.14±0.19      0.32±0.20      0.35±0.37
  Eosinophils (%)             0.09±0.03       0.03±0.02            0.08±0.03                      0.21±0.36       0.08±0.05      0.07±0.04      0.10±0.03
  RBCs (×10^12^/L)            7.51±0.14       7.18±0.57            7.46±0.44                      7.45±0.24       7.26±0.90      7.11±0.67      7.01±0.68
  Hb (g/L)                    141.80±5.12     138.83±10.07         138.04±5.60                    140.80±7.40     138.17±14.12   132.57±11.00   133.20±15.47
  Hematocrit                  0.44±0.01       0.43±0.03            0.43±0.02                      0.44±0.02       0.43±0.03      0.42±0.03      0.42±0.04
  MCV (fL)                    58.64±1.68      59.70±1.73           57.92±2.00                     58.50±1.20      59.78±3.76     58.39±2.62     60.22±1.68
  MCH (pg)                    18.86±0.71      19.38±0.56           18.56±0.73                     18.92±0.63      19.12±0.62     18.66±0.60     18.94±0.59
  MCHC (g/L)                  321.60±4.88     324.83±3.97          320.80±4.44                    323.00±4.30     319.83±9.95    319.57±5.71    314.80±11.43
  RDW-CV (%)                  13.26±0.63      13.37±0.45           13.34±0.44                     13.16±0.34      14.32±3.38     14.00±1.04     14.98±2.93
  Platelet count (×10^9^/L)   751.20±239.82   630.67±159.65        736.00±104.9                   545.60±261.68   586.00±189.9   727.57±84.60   756.60±74.29
  PDW-CV (%)                  14.94±0.05      14.90±0.09           14.88±0.08                     14.96±0.13      14.95±0.08     14.81±0.11     14.88±0.18
  MPV (fL)                    6.88±0.08       6.83±0.08            6.86±0.18                      6.86±0.25       6.78±0.12      6.73±0.11      6.76±0.25
  Plateletcrit (%)            0.57±0.18       0.48±0.13            0.56±0.17                      0.42±0.20       0.44±0.14      0.54±0.06      0.57±0.06

**Notes:** Results given as means ± SD (^a^*P*\<0.05 compared with control).

**Abbreviations:** Hb, hemoglobin; MCH, mean corpuscular Hb; MCHC, MCH concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; NPs, nanoparticles; PDW-CV, platelet-distribution width coefficient of variation; RBCs, red BCs; RDW-CV, RBC-distribution-width coefficient of variation; WBCs, white blood cells.

###### 

Biochemical analysis of liver, renal, and lipid profiles

  Parameters                Control            TiO~2~ NPs (mg/kg)   Fe~3~O~4~-TiO~2~ NPs (mg/kg)                                                            
  ------------------------- ------------------ -------------------- ------------------------------ ------------------ ------------------ ------------------ -----------------
  Liver profile                                                                                                                                             
   TBil (µmol/L)            1.37±0.46          1.28±0.63            0.90±0.37                      1.82±0.91          1.18±0.61          1.96±0.74          1.64±1.03
   TP (g/L)                 51.68±1.50         51.47±0.68           51.23±2.2                      52.20±1.35         51.32±2.80         50.41±1.8          49.40±1.40
   Alb (g/L)                26.85±1.04         27.03±0.19           26.25±1.43                     27.52±0.79         26.68±1.34         25.41±1.22         25.7±1.22
   Glob (g/L)               24.83±0.74         24.43±0.58           24.98±1.04                     24.68±1.04         24.63±1.58         25.00±2.69         23.70±0.60
   ALT (U/L)                50.83±5.78         47.00±5.40           46.33±5.05                     36.40±2.19^b^      42.00±4.52^a^      44.86±5.08         37.6±6.11^b^
   AST (U/L)                134.00±29.40       99.00±15.92^b^       110.17±9.58                    83.00±11.38^b^     94.00±11.28^b^     95.00±14.10^b^     91.20±6.34^b^
   AST/ALT                  2.62±0.42          2.11±0.23^a^         2.40±0.28                      2.29±0.37          2.24±0.09          2.12±0.27^a^       2.47±0.37
   ALP (U/L)                289.83±28.30       297.67±70.11         247.83±42.40                   274.80±61.65       273.33±52.34       318.00±84.06       224.80±30.03
  Renal profile                                                                                                                                             
   Urea nitrogen (mmol/L)   7.15±0.36          6.49±0.74            5.71±0.45^b^                   6.03±0.61^b^       6.62±0.31          6.18±0.57^a^       6.31±0.57
   Creatinine (µmol/L)      35.56±7.00         28.27±3.82^a^        28.65±5.47                     28.28±3.10         29.85±5.12         29.69±3.15         30.80±3.02
   UrcA (µmmol/L)           166.17±64.13       115.33±12.29         124.00±19.12                   119.60±13.92       105.67±32.44^b^    99.57±14.37^b^     98.80±22.63^b^
  Lipid profile                                                                                                                                             
   Chol (mmol/L)            1.35±0.16          1.50±0.06            1.33±0.20                      1.39±0.16          1.33±0.11          1.32±0.16          1.59±0.31
   TG (mmol/L)              0.90±0.29          0.77±0.27            0.80±0.14                      0.78±0.28          1.08±0.28          0.94±0.24          1.06±0.29
   HDL-C (mmol/L)           0.47±0.05          0.49±0.03            0.44±0.08                      0.47±0.07          0.45±0.03          0.48±0.08          0.51±0.13
   LDL-C (mmol/L)           0.43±0.04          0.52±0.05^a^         0.46±0.08                      0.46±0.05          0.45±0.04          0.46±0.05          0.57±0.10^b^
   Glucose (mmol/L)         12.87±2.71         10.08±1.70^a^        11.10±0.62                     10.85±1.05         11.58±1.19         11.34±1.38         11.34±1.33
  Cardiac profile                                                                                                                                           
   CK (U/L)                 3,589.80±          1,881.20±            3,019.30±                      2,096.00±          2,588.00±          2,252.70±          2,145.00±
                            1,758.30           897.60^a^            328.05                         617.80             1,100.70           873.01             377.16
   CK-MB (U/L)              645.83±149.36      499.00±82.98         526.17±72.96                   410.20±66.94^b^    410.67±96.97^b^    397.71±99.94^b^    419.60±92.29^b^
   Amy (U)                  2,457.67± 162.98   2,422.33± 112.64     2,333.17± 237.82               2,427.60± 255.11   2,384.33± 150.82   2,353.14± 145.86   2,443.80± 76.40
   GPDA (U/L)               74.33±11.84        74.67±8.24           73.33±14.56                    78.20±11.08        77.83±12.70        78.00±14.21        67.40±17.39
  Electrolyte profile                                                                                                                                       
   K (mmol/L)               9.41±0.54          8.63±0.46            8.55±0.55                      7.89±0.36          8.87±2.36          7.66±0.53^a^       8.48±1.33
   Cl (mmol/L)              98.52±0.84         100.90±0.63          99.95±1.18                     100.58±1.11        100.97±1.24        100.70±3.14        101.42±2.12^a^
   Ca (mmol/L)              2.46±0.08          2.52±0.01            2.51±0.07                      2.54±0.08          2.53±0.09          2.49±0.06          2.49±0.09
   Mg (mmol/L)              0.90±0.08          0.83±0.04            0.87±0.05                      0.86±0.05          0.87±0.05          0.86±0.07          0.84±0.05
   P (mmol/L)               2.51±0.18          2.16±0.14^a^         2.43±0.22                      2.37±0.22          2.07±0.20^b^       2.23±0.24          2.09±0.29^a^

**Notes:** Results given as means ± SD (^a^*P*\<0.05, ^b^*P*\<0.01 compared with control).

**Abbreviations:** Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; Amy, amylase; AST, aspartate transaminase; Chol, total cholesterol; CK, creatine kinase; CK-MB, creatinine kinase, Glob, globulin; GPDA, glycylproline dipeptidyl aminopeptidase; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol; MB isoenzyme; TBil, total bilirubin; TG, triglycerides; TP, total protein; UrcA, uric acid.
